![Diabetic macular oedema: under‐represented in the genetic analysis of diabetic retinopathy - Broadgate - 2018 - Acta Ophthalmologica - Wiley Online Library Diabetic macular oedema: under‐represented in the genetic analysis of diabetic retinopathy - Broadgate - 2018 - Acta Ophthalmologica - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/23d3e9f3-02c8-4dd7-94e0-3f0db68dbd62/aos.2018.96.issue-a111.cover.jpg)
Diabetic macular oedema: under‐represented in the genetic analysis of diabetic retinopathy - Broadgate - 2018 - Acta Ophthalmologica - Wiley Online Library
![Associations with sight-threatening diabetic macular oedema among Indigenous adults with type 2 diabetes attending an Indigenous primary care clinic in remote Australia: a Centre of Research Excellence in Diabetic Retinopathy and Telehealth Associations with sight-threatening diabetic macular oedema among Indigenous adults with type 2 diabetes attending an Indigenous primary care clinic in remote Australia: a Centre of Research Excellence in Diabetic Retinopathy and Telehealth](https://bmjophth.bmj.com/content/bmjophth/6/1/e000559/F1.large.jpg)
Associations with sight-threatening diabetic macular oedema among Indigenous adults with type 2 diabetes attending an Indigenous primary care clinic in remote Australia: a Centre of Research Excellence in Diabetic Retinopathy and Telehealth
![Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials - The Lancet Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials - The Lancet](https://www.thelancet.com/cms/asset/6d79da4c-93a3-46de-af9b-484ab1913b53/gr1.jpg)
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials - The Lancet
![Treatment of Diabetic Macular Oedema in the context of Non-Tractional Proliferative Diabetic Retinopathy | Institut de la Màcula Treatment of Diabetic Macular Oedema in the context of Non-Tractional Proliferative Diabetic Retinopathy | Institut de la Màcula](http://www.institutmacula.com/wp-content/uploads/Izquierda-20160606@083727-RGB-1024x751.jpg)